Use

The VENTANA FOLR1 (FOLR1‑2.1) RxDx Assay is an FDA‑approved qualitative immunohistochemical assay using a mouse monoclonal anti‑FOLR1 antibody, intended to assess Folate Receptor alpha (FRα) protein in formalin‑fixed, paraffin‑embedded (FFPE) ovarian cancer tissue. It serves as an aid in identifying patients with epithelial ovarian cancer (including primary peritoneal or fallopian tube cancer) who may be eligible for targeted therapy with the FRα‑directed drug ELAHERE™ (mirvetuximab soravtansine‑gynx); results should be interpreted by a qualified pathologist in context of histology and controls.